The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
Humans
Female
B7-H1 Antigen
CD8-Positive T-Lymphocytes
Programmed Cell Death 1 Receptor
/ metabolism
Neoplasm Recurrence, Local
/ pathology
Lymphocytes, Tumor-Infiltrating
Tumor Microenvironment
Prognosis
Endometrial Neoplasms
/ pathology
Forkhead Transcription Factors
/ metabolism
Biomarkers, Tumor
/ metabolism
clinical outcome
endometrial cancer
immune microenvironment
low grade
multiplex quantitative immunofluorescence
prognosis
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
04
09
2022
received:
18
06
2022
accepted:
21
09
2022
pubmed:
29
9
2022
medline:
11
11
2022
entrez:
28
9
2022
Statut:
ppublish
Résumé
Endometrial tumors show substantial heterogeneity in their immune microenvironment. This heterogeneity could be used to improve the accuracy of current outcome prediction tools. We assessed the immune microenvironment of 235 patients diagnosed with low-grade, early-stage endometrial cancer. Multiplex quantitative immunofluorescence was carried out to measure CD8, CD68, FOXP3, PD-1, and PD-L1 markers, as well as cytokeratin (CK), on tissue microarrays. Clustering results revealed five robust immune response patterns, each associated with specific immune populations, cell phenotypes, and cell spatial clustering. Most samples (69%) belonged to the immune-desert subtype, characterized by low immune cell densities. Tumor-infiltrating lymphocyte (TIL)-rich samples (4%) displayed high CD8
Identifiants
pubmed: 36169332
doi: 10.1002/path.6012
pmc: PMC9828119
doi:
Substances chimiques
B7-H1 Antigen
0
Programmed Cell Death 1 Receptor
0
Forkhead Transcription Factors
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
426-436Informations de copyright
© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Références
Science. 2021 Jun 11;372(6547):
pubmed: 34112666
Virchows Arch. 2021 Dec;479(6):1167-1176
pubmed: 34420090
Cell. 2020 Feb 20;180(4):729-748.e26
pubmed: 32059776
Int Immunopharmacol. 2020 Nov;88:106931
pubmed: 32889237
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Mod Pathol. 2003 Nov;16(11):1148-58
pubmed: 14614055
Aging (Albany NY). 2020 Nov 6;12(21):22152-22173
pubmed: 33159014
J Cell Mol Med. 2020 Jul;24(14):7767-7777
pubmed: 32424934
Dis Markers. 2020 Jan 28;2020:1805764
pubmed: 32076456
BMC Cancer. 2020 Feb 17;20(1):127
pubmed: 32066405
Histopathology. 2016 May;68(6):916-24
pubmed: 26416160
Gynecol Oncol. 2009 Jul;114(1):105-10
pubmed: 19411095
Mod Pathol. 2021 Dec;34(12):2229-2241
pubmed: 34215851
Front Oncol. 2021 Sep 01;11:612450
pubmed: 34540651
Microsyst Nanoeng. 2019 Nov 6;5:59
pubmed: 31700674
Biology (Basel). 2021 Aug 30;10(9):
pubmed: 34571723
Int J Mol Sci. 2019 May 15;20(10):
pubmed: 31096567
Int J Gynecol Cancer. 2020 Dec;30(12):2002-2007
pubmed: 33046573
Mod Pathol. 2022 Apr;35(4):564-576
pubmed: 34732839
Nat Rev Dis Primers. 2021 Dec 9;7(1):88
pubmed: 34887451
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Int Immunopharmacol. 2020 Sep;86:106735
pubmed: 32619957
Int J Gynecol Pathol. 2019 Sep;38(5):404-413
pubmed: 30134343
Virchows Arch. 2020 Dec;477(6):845-856
pubmed: 32594230
J Reprod Immunol. 2015 Jun;109:7-16
pubmed: 25613542
J Pathol. 2020 Mar;250(3):336-345
pubmed: 31829441
Bioinformatics. 2014 Oct;30(19):2811-2
pubmed: 24930139
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Cancers (Basel). 2021 Feb 14;13(4):
pubmed: 33672863
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Int J Gynecol Pathol. 2017 Nov;36(6):540-549
pubmed: 28114190
Ann Oncol. 2018 May 1;29(5):1180-1188
pubmed: 29432521
Mod Pathol. 2020 Dec;33(12):2507-2519
pubmed: 32591586
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Clin Cancer Res. 2016 Aug 15;22(16):4215-24
pubmed: 27006490
Cancer Cell. 2015 Dec 14;28(6):785-799
pubmed: 26678340
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Cancer Microenviron. 2019 Dec;12(2-3):169-179
pubmed: 31134527
J Pathol. 2022 Jul;257(3):340-351
pubmed: 35262923
Int J Gynecol Cancer. 2011 Dec;21(9):1628-34
pubmed: 21897268
J Pathol. 2020 Mar;250(3):323-335
pubmed: 31829442
Anticancer Res. 2004 Sep-Oct;24(5C):3335-42
pubmed: 15515429
Eur J Cancer. 2016 Jun;60:1-11
pubmed: 27038842
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Int J Gynecol Cancer. 2018 Jan;28(1):59-68
pubmed: 29053481
Eur J Cancer. 2016 Dec;69:51-60
pubmed: 27816832
Medicine (Baltimore). 2021 May 28;100(21):e26170
pubmed: 34032778